HYPERCOAGULABILITY AND SECONDARY HYPERFIBRINOLYSIS MAY BE RELATED TO ABNORMAL LIPID-METABOLISM IN PATIENTS TREATED WITH CONTINUOUS AMBULATORY PERITONEAL-DIALYSIS
M. Kobayashi et al., HYPERCOAGULABILITY AND SECONDARY HYPERFIBRINOLYSIS MAY BE RELATED TO ABNORMAL LIPID-METABOLISM IN PATIENTS TREATED WITH CONTINUOUS AMBULATORY PERITONEAL-DIALYSIS, Nephron, 76(1), 1997, pp. 56-61
To investigate abnormalities in the hemostatic and fibrinolytic system
in CAPD patients, parameters of coagulation, anticoagulation, fibrino
lysis, and platelet function were measured in 21 CAPD patients and 20
healthy controls. The CAPD patients had significantly higher levels of
factor (F) IX, FVII, FX, antithrombin III, thrombin/antithrombin III
complex, protein C, protein S, thrombomodulin, fibrinogen, fibrinopept
ide A, plasminogen, FXIII, alpha(2)-plasmin inhibitor, alpha(2)-plasmi
n inhibitor/plasmin complex, D-dimer, fibrinopeptide B beta 15-42, and
beta-thromboglobin than the healthy controls. The CAPD patients also
showed a shorter prothrombin time. However, tissue plasminogen activat
or, plasminogen activator inhibitor-1 and platelet factor-4 did not sh
ow any significant differences from the levels in healthy controls. Th
ere was a significant positive correlation between many of the blood p
arameters and serum lipids. These results demonstrate that hypercoagul
ability and secondary hyperfibrinolysis occur in CAPD patients, and su
ggest that these changes may be related to abnormalities in lipid meta
bolism.